Journal of Clinical Oncology
Articles in this Issue
Molecular markers associated with survival in PD-L1– high non-small cell lung cancer treated with first-line immunotherapy versus chemoimmunotherapy.
e20607 Background: It is unclear which patients with advanced non-small cell lung cancer (NSCLC) with high programmed death-ligand 1 (PD-L1) tumor proport...
9MW2821, a novel Nectin-4 antibody-drug conjugate (ADC), combined with toripalimab in treatment-naïve patients with locally advanced or metastatic urothelial carcinoma (la/mUC): Results from a phase 1b/2 study.
4519 Background: Nectin-4 is an adhesion molecule that is highly expressed in variety of solid tumors. Previous study of 9MW2821 has shown promising effic...
Outcomes of continuing neoadjuvant-intent immunotherapy for advanced, resectable cutaneous squamous cell carcinoma post-operatively.
e18085 Background: Cutaneous Squamous Cell Carcinoma (cSCC) of the head and neck is mediated by ultraviolet radiation and associated with multifocal disea...
Efficacy and safety of taxane platinum doublet chemotherapy with triple oral metronomic chemotherapy and low dose nivolumab as neoadjuvant therapy in locally advanced head and neck squamous cell carcinoma.
e18103 Background: In India, 80–90% of patients with head and neck squamous cell carcinoma (HNSCC) present with locally advanced disease. Randomized studi...
Decoding tumor evolution in advanced ovarian cancer: Proteogenomic insights before and after neoadjuvant chemotherapy.
e17582 Background: Platinum-based neoadjuvant chemotherapy (NACT) is a cornerstone in advanced ovarian cancer (OC) treatment. However, biomarkers predicti...
Residents’ understanding of cancer prognosis: Does the level of training or oncology rotation experience affect residents’ perception of cancer prognosis?
e21033 Background: Over the last decade, immunotherapy has become a first-line therapy option alongside chemotherapy for certain cancers, providing durabl...
Pembrolizumab (pembro) with chemoradiotherapy (CRT) as treatment for muscle-invasive bladder cancer (MIBC): Long-term follow up of secondary endpoints of efficacy including overall survival of the PCR-MIB phase II clinical trial (ANZUP 1502).
4577 Background: We hypothesised pembro could be added without undue toxicity to CRT and would improve efficacy in patients (pts) with MIBC. M...
The effect of endocrine therapy omission on survival in ER-negative PR-low (1–10%) early-stage breast cancer treated with chemotherapy.
521 Background: The effect of endocrine therapy omission on outcomes in breast cancer (BC) with low progesterone receptor (PR) expression (1–10%) is unkno...
Unique mutational landscape and therapeutic implications in non-small cell lung cancer with comorbid fibrotic interstitial lung disease.
8061 Background: Patients with established interstitial lung disease (ILD) have both increased risk of developing non-small cell lung cancer (NSCLC) and h...
Global burden of non-retinoblastoma eye cancer in 204 countries and territories, 1990–2021.
e18081 Background: Non-retinoblastoma eye (NRB) cancers include different malignancies affecting eye structures, including uveal melanoma, sebaceous gland...
Telisotuzumab adizutecan (ABBV-400; Temab-A), a c-Met protein–targeting antibody-drug conjugate (ADC), in patients (pts) with advanced <i>EGFR</i> -mutated (MT) non-squamous (NSQ) non-small cell lung cancer (NSCLC): Results from a phase 1 study.
8512 Background: c-Met protein (also known as MET protein) expression is increased in NSCLC and is a negative prognostic i...
Additive clinical utility of tissue biomarkers of microsatellite instability (MSI) status and tumor mutational burden (TMB) to predict immune checkpoint inhibitor (ICI) effectiveness for real-world patients with metastatic castration-resistant prostate cancer (mCRPC).
5064 Background: FoundationOneCDx (F1CDx) supports two FDA-approved biomarkers to guide treatment decisions for ICI for patients with mCRPC: MSI status an...
Intravenous selenium to prevent oral mucositis in patients with lymphoma or myeloma undergoing high-dose therapy followed by autologous hematopoietic cell transplantation: A double-blind randomized trial.
12091 Background: Oral mucositis (OM) is a frequent complication in patients with lymphoma and myeloma receiving high-dose therapy (HDT) and autologous he...
Inflammatory bowel disease and risk of cancer: A nationwide study.
e15663 Background: Inflammatory bowel disease (IBD), including Crohn’s disease (CD) and ulcerative colitis (UC), is a chronic inflammatory condition of th...
Electronic patient-reported outcomes (ePRO)-based alerts deployed in clinical practice to inform treatment burden and care management in pancreatic cancer.
11130 Background: Pancreatic ductal adenocarcinoma (PDAC) is characterized by aggressive growth and late-stage diagnosis. About 20% of patients are eligib...
A phase II trial of pembrolizumab and lenvatinib in recurrent or persistent clear cell ovarian carcinoma (NCT05296512).
5515 Background: Clear cell ovarian carcinoma (CCOC) is a chemoresistant subtype of ovarian cancer. Immune checkpoint inhibitors have been reported to hav...
Efficacy and safety of standard versus extended interval dosing of PD-1/PD-L1 immune checkpoint inhibitors in solid tumors: A meta-analysis of 4,063 patients.
e14586 Background: PD-1/PD-L1 immune checkpoint inhibitors (ICIs) are used as monotherapy or in combination for various late-stage solid tumors. There are...
Infusion product characteristics to predict response to tumor-infiltrating lymphocyte (TIL) therapy in metastatic melanoma (MM).
9516 Background: Identification of the TIL therapy product (TILp) characteristics associated with objective response to therapy is critical to improve fut...
Retrospective comparison of abatacept (Aba) and half-dose posttransplant cyclophosphosphamide (PTCy) compared with standard dose PTCy GVHD prophylaxis.
e18555 Background: Aba and PTCy have improved outcomes for alternative donor transplants and have expanded the donor pool. However, Aba in the approved sc...
Immunohistochemistry-based molecular subtyping in muscle-invasive bladder cancer: Predicting response to neoadjuvant chemotherapy.
e16590 Background: Muscle-invasive bladder cancer (MIBC) presents a heterogeneous response to perioperative chemotherapy, with significant variability in...
Immune checkpoint inhibitors for ovarian cancer: A retrospective analysis of efficacy and tolerability.
e17574 Background: Ovarian cancer (OC) is the leading cause of gynecological cancer-related deaths. Despite standard treatments, most advanced cases recur...
Safety and efficacy of ABBV-706, a seizure-related homolog protein 6 (SEZ6)–targeting antibody-drug conjugate, in high-grade neuroendocrine neoplasms.
105 Background: SEZ6 is a potential neuroendocrine lineage marker that is expressed in small cell lung cancer (SCLC) and high-grade neuroendocrine neoplas...
International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) classification and regression tree analysis to characterize objective response rates (ORR) in metastatic renal cell carcinoma (mRCC).
4532 Background: Therapies for mRCC have evolved significantly, making treatment decisions more complex. We used machine learning (ML) to identify whether...
Machine learning to predict immune-related adverse events in cancer patients treated with ICIs.
e13620 Background: Immune-related adverse events (irAEs) secondary to treatment with immune checkpoint inhibitors (ICIs) pose a major challenge in cancer...
Food insecurity, dietary quality, and cardiovascular risk in early childhood cancer survivors.
10060 Background: Childhood cancer survivors (CCS) experience cardiovascular (CV) mortality 7 times higher than the general population. Low-income and Bla...